Articles On Orthocell (ASX:OCC)

The ASX200 closed up 0.39% at 8,013 points. The bank stocks rallied leading the index higher, but Energy and mining stocks slumped in the wake of falling commodity prices. Financials was the best performing sector, up 1.45%, followed...

WA regenerative medicine company Orthocell has started selling its dental bone repair product in Canada — a market estimated to worth to be about $60 million.

The ASX200 has been up around 0.5% at 8,025 points. Bank stocks have surged and dragged the market higher with the big 4 all outperforming and dragging the bourse higher. In commodities, the gold price is fetching more than US$2500 an...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Fraser Palamara explains why the Canadian market is so important for Aussie pharmaceutical Orthocell. Tune in to get the latest. While Or...

Orthocell (ASX:OCC) has confirmed it’s sold its first units of collagen-based bone repair product Striate+ in Canada through distro partner BioHorizons. The move effectively represents a further expansion for the company into another we...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Stockhead’s Sarah Hughan sits down with Orthocell (ASX:OCC) chair John Van Der Wielen to get the short end of the long story on the company’s latest news. Regenerative medicine company Orthocell is further expanding the sales of its product...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Several ASX healthcare companies are proudly manufacturing products in Australia  Polynovo, Optiscan and Trajan Group all have manufacturing facilities in Melbourne Orthocell says government funding can boost manufacturing capabilities of...

Western Australia wanting to diversity beyond resources and become a global leader in health and medical life sciences Cook Government to invest $16m into driving a connected and innovative ecosystem for WA’s health and medical research se...

The 2024 Bioshares Biotech Summit is being held in Fremantle from July 12-13 Day two’s focus is on new companies, diagnostics and those following a new direction Trends in healthcare and biotech sector a focus as investor sentiment improve...

Shares in WA regenerative medicine company Orthocell are up after it received regulatory approval to start selling its dental bone repair product in Canada.

The ASX200 had a strong day closing up 0.93%. All sectors closed in the green with top performer Real Estate jumping 1.5%,  followed closely by IT and Healthcare. In this bulletin, we’ll discuss Renascor, Telix Pharmaceuticals, Orthoc...

ASX 200 punches it, record highs back in view  11 of 11 sectors higher, like a well-oiled machine  Great day for small caps, goldies and Augustus Minerals Local markets surged this morning after yet another record-breaking night for Wa...

  Orthocell receives regulatory approval to sell dental guided bone regeneration product Striate+ in Canada Approval complements existing approvals for Striate+ in other key markets including the US Orthocell’s distribution partner Bio Hor...

ASX 200 closes 0.16pc lower after modest rally from morning lows  Six of 11 sectors lower, after rate-sensitive sectors improve after lunch  Killi Resources surges again with a late surge to dethrone Infini   Local markets have trimmed...

ASX 200 rises strongly on Tuesday, closes up +0.86pc  All 11 sectors in the green, like Kermit on a golf course  Top small cap was Killi Resources with a bumper +83.7pc surge   Local markets jumped on Tuesday, erasing all of Monday’s l...

  Special Report: Dropping milestone numbers this week is the Perth-based regenerative medtech Orthocell, for which record quarterly and full year revenue has been driven by a huge uptick in demand across the company’s flagship healing solu...

Orthocell (ASX:OCC) shares jumped close to 5% heading into afternoon trade as the company flagged record yearly revenues. The company sells two keystone products – Striate+ and Remplir respectively – both aimed at regenerating bones and...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin PERTH, Australia, July 2, 2024 /PRNewswire/ — Bridgewest Perth Pharma, global pha...

Aussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sectors were the biggest losers among all 11 sectors Chinese EV stocks fell ahead of expected EU tariff hikes   Aussie shares slipped after the K...

Orthocell (ASX:OCC) has taken a significant step forward in its efforts to introduce its SmrtGraft product to the Australian market. The company has submitted an application to the Therapeutic Goods Administration (TGA) seeking approval to...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

WA regenerative medicine company Orthocell has reported a near 100 per cent success rate for its dental bone repair product during a recent clinical study.

Race Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning after sharing the results from recent preclinical studies conducted at Oncolines B.V. in the Netherlands. In these studies, bisantrene (Race...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

The ASX200 closed around a quarter of a per cent up with Consumer discretionary topping the gains, finishing nearly half a per cent up and Utilities and Industrials both losing around half a per cent. In the green Mineral explorer IGO...

Regenerative medicine company Orthocell (ASX:OCC) has published encouraging findings from its Remplir nerve regeneration clinical trial, unveiling promising progress in its peripheral nerve repair journey – offering hope for millions of peo...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Perth clinical dermatology company Botanix has been elevated into the All Ordinaries index made up of the top 500 companies listed on the Australian Securities Exchange.

Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study.

Regenerative medicine company Orthocell says it has successfully completed the first stage of a pivotal US market authorisation study for its nerve repair product, paving the way for global expansion.

Argenica granted US FDA’s Rare Pediatric Disease Designation Orthocell completes Remplir study, targets US$1b+ nerve repair device market LTR Pharma progresses Erectile Dysfunction study   Argenica gets FDA approval Argenica Therapeutics...

Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun. That was the message today as four biotech companies and Life Sciences WA presented to 200 brokers and...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

The $3.5m of shares have been taken up by prominent investors Chris Ellison, Rod Jones, Malcolm and Tonya McCusker and Michael Malone, along with the Merchant Biotech Fund.

  Local markets end slightly lower Telco Sector jumps 1.5pc Small Caps led by Way2Vat   The ASX200 has ended a second slumbrous session slightly lower, with a little dribble in the shape of the Star Casino at the corner of its mouth. US M...

Orthocell (ASX:OCC) has announced the final results from its clinical study comparing OrthoATI to surgery to treat severe, chronic, treatment-resistant lateral epicondylitis.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

In drug development there’s a narrow window to get to market and long delays tend to be fatal – and not just for the patients. Ten years ago, Pharmaxis was confident of US Food and Drug Administration approval for its cystic fibrosis treatm...

Perth-based regenerative medicine company Orthocell has appointed famed plastic surgeon Fiona Wood to its board as a non-executive director.

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...